Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgad610 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Nipun Lakshitha de Silva und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Faculty of Medicine, General Sir John Kotelawala Defence University, Ratmalana 10390, Sri Lanka. Hauptthemen laut MEDLINE: Drug Costs, Rare Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MRC, and, National Institute for Health and Care Research (NIHCR).
Abstract (Originalsprache)
Context
Clinical endocrinology encompasses many diseases requiring long-term drug therapy. Prohibitive pricing of some endocrine drugs classified as essential by the World Health Organization has created suboptimal care of patients with endocrine disorders. Evidence acquisition This review is based on evidence obtained from several databases and search engines including PubMed, Google, and Google Scholar; reference searches; manual searching for web pages of international regulatory bodies; and the authors’ experience from different healthcare settings. Evidence synthesis After the expiry of a patent, generic versions with the opportunity for increased availability and a price reduction are expected. There are access barriers worldwide for many off-patent endocrine drugs. The high price is the main issue for several medicines including insulin, hydrocortisone, testosterone, and gonadotropins. This is caused by several factors including the market monopoly due to the lack of registered generics or suppliers limiting the benefit of competition and a complex supply chain. Additionally, the lack of some medicines has been concerning due to market factors such as the relatively small number of patients, making it less attractive for the manufacturers. Commissioning of nonprofit manufacturers and state manufacturing as well as strict price control measures could alleviate this situation.
Conclusion
Lack of availability and disproportionate price inflation affecting essential off-patent endocrine therapies is common due to several interrelated factors. Global collaboration among healthcare organizations with the support of policymaking bodies might be needed to mitigate this.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Faculty of Medicine, General Sir John Kotelawala Defence University, Ratmalana 10390, Sri Lanka.
- Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Colombo 00800, Sri Lanka.
- Department of Endocrinology, Bharti Hospital, Karnal, Haryana 132001, India.
- University Centre for Research and Development, Chandigarh University, Mohali 140413, India.
- Department of Metabolism, Digestion and Reproduction, Imperial College, W12 0NN, London, UK.
- Diabetes and Hormone Centre, Colombo 00200, Sri Lanka.
ORCID-Profile: Nipun Lakshitha de Silva, Karim Meeran, Channa N Jayasena
Förderung
- MRC
- and
- National Institute for Health and Care Research (NIHCR)
- NIHR Biomedical Research Centre Funding Scheme
- NIHR/Imperial Clinical Research Facility
Zitieren
APA
de Silva, N. L., Dissanayake, H., Kalra, S., Meeran, K., Somasundaram, N. P., & Jayasena, C. N. (2024). Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad610
Vancouver
de Silva NL, Dissanayake H, Kalra S, Meeran K, Somasundaram NP, Jayasena CN. Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad610
BibTeX
@article{deSilva2024,
author = {de Silva, Nipun Lakshitha and Dissanayake, Harsha and Kalra, Sanjay and Meeran, Karim and Somasundaram, Noel P and Jayasena, Channa N},
title = {Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgad610}
}
EUVIMED